Highlights 

  • RMD’s Q1FY26 revenue rose 9% year-on-year to USD 1,335.6 million. 
  • In Q1FY26, Income from operations increased 15% compared to the prior-year quarter. 
  • Cash and cash equivalents climbed to USD 1.38 billion as of 30 September 2025. 

ResMed Inc. (ASX:RMD), a provider of digital health technologies and cloud-connected medical devices, reported higher revenue for the quarter ended 30 September 2025 (Q1FY26). The company generated revenue of USD 1,335.6 million in the first quarter of FY26, compared with USD 1,224.5 million in the corresponding period last year, representing a 9% year-on-year increase. 

The revenue growth was supported by rising global demand for sleep devices, masks, and accessories. Geographic expansion and continued growth in Residential Care Software also contributed to the quarterly performance. 

Operating Income Shows Double-Digit Increase 

Income from operations reached USD 446.5 million in Q1 FY26, up from USD 387.3 million in Q1 FY25. This marked a 15% year-on-year increase. The improvement was attributed to manufacturing efficiencies, logistics optimisation, and lower component costs. 

The company also benefited from disciplined operating expense management and margin expansion during the quarter. 

Cash Position Strengthens on Operating Cash Flow 

ResMed reported cash and cash equivalents of USD 1.38 billion at the end of the quarter, compared with USD 0.43 billion in the prior-year period. The increase was supported by the operating cash flow of USD 457 million. 

December CDI Update Released 

On 6 January 2026, the company released an update on its CHESS Depositary Interests (CDIs). The company reported that total CDIs increased by 62,160 to 579.45 million in December 2025. 

The movement was driven by transfers between ASX-listed CDIs and NYSE-listed common stock, as well as employee equity issuance and buyback activity. 

Company Outlook 

ResMed anticipates ongoing revenue expansion, supported by the widening international uptake of its health solutions. Key focus areas remain the development of innovative connected devices, software platforms, and scalable home healthcare delivery models. The company's financial outlook stresses a commitment to operational excellence, including rigorous cost discipline and manufacturing efficiency, to facilitate margin growth, enhance operating leverage, and ensure robust cash flow. Funds would be strategically deployed to balance shareholder returns (dividends and buybacks) with investments in technology and targeted acquisitions.  

Share Performance of RMD 

RMD shares rose 1.16% to close at AUD 36.50 per share on 07 January 2026. Over the past year, the stock has declined 2.80%. It is down 4.97% over the past month and 6.98% over six months, while gaining 6.26% over the past nine months and 1.56% month-to-date. The 52-week high for RMD is AUD 45.25, recorded on 25 August 2025, while the 52-week low is AUD 32.04, reached on 7 April 2025. 

Support and Resistance Summary  

Note 1: Past performance is neither an Indicator nor a guarantee of future performance. 

Note 2: The reference date for all price data, and currency, is 07 January 2026. The reference data in this report has been partly sourced from EODHD/Others. 

  

Technical Indicators Defined:  

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.